{"schema_version":"secwatch.filing_event.v1","accession":"0001822479-24-000038","form_type":"8-K","ticker":"SHC","cik":"0001822479","company_name":"Sotera Health Co","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.680284+00:00","generated_at":"2026-05-31T13:12:47.446557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sotera Health Q2 net revenue up 8.3% to $277M; adj. EBITDA up 6.9% to $137M","bullets":["Net income $9M ($0.03 diluted) vs $24M ($0.08) in Q2 2023; decline due to debt refinancing charges.","Adjusted EPS $0.19 vs $0.20; higher interest expense weighed on earnings.","Refinanced debt structure, extending maturities to 2031; reaffirmed 2024 outlook.","First-half 2024 revenue $525M (+10.3%), adj. EBITDA $249M (+9.8%), adj. EPS $0.32.","All three segments (Sterigenics, Nordion, Nelson Labs) reported volume increases in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001822479-24-000038","json":"https://secwatch.observer/filing/0001822479-24-000038.json","markdown":"https://secwatch.observer/filing/0001822479-24-000038.md","text":"https://secwatch.observer/filing/0001822479-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822479/000182247924000038/0001822479-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822479/000182247924000038/shc-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:12:47.446557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}